Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Efforts to develop efficacious antidepressant agents with novel mechanisms have been largely unsuccessful since the 1950’s until the discovery of ketamine, an N-methyl-d-aspartate (NMDA) receptor antagonist that produces rapid and sustained antidepressant actions even in treatment-resistant patients. This finding has ushered in a new era for the development of novel rapid-acting antidepressants that act at the NMDA receptor complex, but without dissociative and psychotomimetic side effects of ketamine. Here, we review the current state of rapid-acting antidepressant drug development, including NMDA channel blockers, glycine site agents, and allosteric modulators, as well as ketamine stereoisomers and metabolites. In addition, we focus on the neurobiological mechanisms underlying the actions of these diverse agents and discuss evidence of convergent mechanisms including increased brain-derived neurotrophic factor signaling, increased synthesis of synaptic proteins, and most notably increased GluR1 and synaptic connectivity in the medial prefrontal cortex. These convergent mechanisms provide insight for potential additional novel targets for drug development (e.g., agents that increase synaptic protein synthesis and plasticity). Importantly, the convergent effects on synapse formation and plasticity also reverse the well-documented neuronal and synaptic deficits associated with stress and depression, and thereby target the underlying pathophysiology of major depressive disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S., Bertolino, A., Zaitsev, E., Gold, B., Goldman, D., Dean, M., et al. (2003) · Cell · doi:10.1016/s0092-8674(03)00035-7 · Cited by 3,888 · cited 1×
“Neurons of the BDNF Val66Met mice are able to synthesize BDNF, but the processing and activity-dependent release of BDNF is restricted, suggesting that the actions of ketamine require BDNF release [65].”
BackgroundTrivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · cited 1×
“monoamine reuptake blockers are modestly effective, require weeks to months of treatment and for many patients multiple prescriptions and/or drug combinations, and still these agents are ineffective in approximately one-third of patients who are considered treatment resistant [4].”
BackgroundAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375
Self-citationmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 10×
“increase in levels of synaptic proteins, including GluA1, PSD95, and synapsin 1 in the mPFC [36, 41].”
BackgroundMethodInfluentialSelf-citationThe State of US Health, 1990-2010: Burden of Diseases, Injuries, and Risk Factors
Murray, C. J. L. (2013) · JAMA · doi:10.1001/jama.2013.13805 · Cited by 2,438
Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms
Citri, A., & Malenka, R. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301559 · Cited by 2,323 · cited 1×
“It represents the ability of neuronal circuits to respond to and store stimuli from multiple inputs and make appropriate adaptive responses to the same or similar future stimuli [46].”
BackgroundNibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109
Self-citation
Research works printed but not linked: 63
- Curtin SC, Warner M, Hedegaard H. Increase in suicide in the United States, 1999–2014. NCHS Data Brief. 2016;241:1–8.
- Sinner B, Graf BM. Modern Anesthetics. In: Schüttler J, Schwilden H, (eds). Handbook of Experimental Pharmacology. 182. Berlin, Heidelberg: Springer; 2008. p. 313–33.
- Henter ID, de Sousa RT, Zarate CA, Jr. Glutamatergic Modulators in Depression. Harv Rev Psychiatry. 2018;26:307–19. · DOI · Paper page
- Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry. 2013;73:1133–41. · DOI · Paper page
- Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K. (R)-Ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psych. 2017;85:e43–e44. · DOI · Paper page
- Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 1993;361:31–39. · DOI · Paper page
- Nicoll RA, Malenka RC. Contrasting properties of two forms of long-term potentiation in the hippocampus. Nature. 1995;377:115–8. · DOI · Paper page
- Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011;32:726–33. · DOI · Paper page
- Hansen KB, Yi F, Perszyk RE, Furukawa H, Wollmuth LP, Gibb AJ, et al. Structure, function, and allosteric modulation of NMDA receptors. J Gen Physiol. 2018;150:1081–105. · DOI · Paper page
- Mealing GA, Lanthorn TH, Murray CL, Small DL, Morley P. Differences in degree of trapping of low-affinity uncompetitive N-methyl-D-aspartic acid receptor antagonists with similar kinetics of block. J Pharmacol Exp Ther. 1999;288:204–10.
- Blanpied TA, Boeckman FA, Aizenman E, Johnson JW. Trapping channel block of NMDA-activated responses by amantadine and memantine. J Neurophysiol. 1997;77:309–23. · DOI · Paper page
- MacQueen G, Frodl T. The hippocampus in major depression: evidence for the convergence of the bench and bedside in psychiatric research? Mol Psychiatry. 2011;16:252–64. · DOI · Paper page
- Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry. 2011;69:754–61. · DOI · Paper page
- Hoeffer CA, Klann E. mTOR signaling: at the crossroads of plasticity, memory and disease. Trends Neurosci. 2010;33:67–75. · DOI · Paper page
- Pazini F, Cunha M, Rosa J, Colla A, Lieberknecht V, Oliveira A, et al. Creatine, similar to ketamine, counteracts depressive-like behavior induced by corticosterone via PI3K/Akt/mTOR pathway. Mol Neurobiol. 2016;53:6818–34. · DOI
- Harraz M, Tyagi R, Cortés P, Snyder S. Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psych. 2016;21:313–9. · DOI · Paper page
- Yang C, Kobayashi S, Nakao K, Dong C, Han M, Qu Y, et al. AMPA receptor activation-independent antidepressant actions of ketamine metabolite (S)-norketamine. Biol Psychiatry. 2018;84:591–600. · DOI · Paper page
- Sutton MA, Taylor AM, Ito HT, Pham A, Schuman EM. Postsynaptic decoding of neural activity: eEF2 as a biochemical sensor coupling miniature synaptic transmission to local protein synthesis. Neuron. 2007;55:648–61. · DOI · Paper page
- Hill JL, Martinowich K. Activity-dependent signaling: influence on plasticity in circuits controlling fear-related behavior. Curr Opin Neurobiol. 2016;36:59–65. · DOI
- Smith MA, Makino S, Kvetnansky R, Post RM. Stress and glucocorticoids affect the expression of brain-derived neurotrophic factor and neurotrophin-3 mRNAs in the hippocampus. J Neurosci. 1995;15):1768–77. · DOI · Paper page
- Chen B, Dowlatshahi D, MacQueen GM, Wang JF, Young LT. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260–5. · DOI · Paper page
- Chen ZY, Jing D, Bath KG, Ieraci A, Khan T, Siao CJ, et al. Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science. 2006;314:140–3. · DOI · Paper page
- Lepack A, Fuchikami M, Dwyer J, Banasr M, Aghajanian G, Duman R. BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol. 2014;18:1.
- Su TP, Chen MH, Li CT, Lin WC, Hong CJ, Gueorguieva R, et al. Dose-related effects of adjunctive ketamine in taiwanese patients with treatment-resistant depression. Neuropsychopharmacology. 2017;42:2482–92. · DOI · Paper page
- Duman RS. Ketamine and rapid-acting antidepressants: a new era in the battle against depression and suicide. F1000Research. 2018; 7:659. · DOI · Paper page
- Fan LZ, Nehme R, Adam Y, Jung ES, Wu H, Eggan K, et al. All-optical synaptic electrophysiology probes mechanism of ketamine-induced disinhibition. Nat Methods. 2018;15:823–31. · DOI · Paper page
- Preskorn S, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-asparate antagonist, CP-101, 606, in patients with treatment-refractory major depressive dosorder. J Clin Psychopharmacol. 2008;28:631–7. · DOI · Paper page
- Park L, Furey M, Nugent AC, Farmer C, Ellis J, Szczepanik J, et al. Neurophysiological changes associated with antidepressant response to ketamine not observed in a negative trial of scopolamine in major depressive disorder. Int J Neuropsychopharmacol. 2019;22:10–8. · DOI · Paper page
- Voleti B, Navarria A, Liu RJ, Banasr M, Li N, Terwilliger R, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry. 2013;74:742–9. · DOI · Paper page
- Yang C, Ren Q, Qu Y, Zhang J, Ma M, Dong C, et al. Mechanistic target of rapamycin-independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psych. 2018;83:1. · doi:10.1016/s0006-3223(18)31419-7
- Zhang K, Toki H, Fujita Y, Ma M, Chang L, Qu Y, et al. Lack of deuterium isotope effects in the antidepressant effects of (R)-ketamine in a chronic social defeat stress model. Psychopharmacol (Berl). 2018;235:3177–85. · DOI
- Shirayama Y, Hashimoto K. Lack of antidepressant effects of (2R,6R)-hydroxynorketamine in a rat learned helplessness Model:comparison with (R)-ketamine. Int J Neuropsychopharmacol. 2018;21:84–8. · DOI · Paper page
- Clements JD, Westbrook GL. Activation kinetics reveal the number of glutamate and glycine binding sites on the N-methyl-D-aspartate receptor. Neuron. 1991;7:605–13. · DOI · Paper page
- Zanos P, Piantadosi SC, Wu HQ, Pribut HJ, Dell MJ, Can A, et al. The prodrug 4-chlorokynurenine causes ketamine-like antidepressant effects, but not side effects, by NMDA/glycineB-site inhibition. J Pharmacol Exp Ther. 2015;355:76–85. · DOI
- Wallace M, White A, Grako KA, Lane R, Cato AJ, Snodgrass HR. Randomized, double-blind, placebo-controlled, dose-escalation study: Investigation of the safety, pharmacokinetics, and antihyperalgesic activity of l-4-chlorokynurenine in healthy volunteers. Scand J Pain. 2017;17:243–51. · DOI · Paper page
- Papp M, Moryl E. Antidepressant-like effects of 1-aminocyclopropanecarboxylic acid and D-cycloserine in an animal model of depression. Eur J Pharmacol. 1996;316:145–51. · DOI
- Malkesman O, Austin DR, Tragon T, Wang G, Rompala G, Hamidi AB, et al. Acute D-serine treatment produces antidepressant-like effects in rodents. Int J Neuropsychopharmacol. 2012;15:1135–48. · DOI · Paper page
- Huang CC, Wei IH, Huang CL, Chen KT, Tsai MH, Tsai P, et al. Inhibition of glycine transporter-I as a novel mechanism for the treatment of depression. Biol Psychiatry. 2013;74:734–41. · DOI
- Chen KT, Tsai MH, Wu CH, Jou MJ, Wei IH, Huang CC. AMPA receptor-mTOR activation is required for the antidepressant-like effects of sarcosine during the forced swim test in rats: insertion of ampa receptor may play a role. Front Behav Neurosci. 2015;9:162.
- Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, et al. The development of rapastinel (Formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. 2017;15:47–56. · DOI · Paper page
- Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, et al. Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract. 2015;21:140–9. · DOI · Paper page
- (Glyx-13), A rapid acting antidepressant, does not increase extracellular levels of dopamine and glutamate in rat medial prefrontal cortex. Proceedings of the American College of Neuropsychopharmacology, Hollywood, Florida, 2016.
- Hascup ER, Hascup KN, Stephens M, Pomerleau F, Huettl P, Gratton A, et al. Rapid microelectrode measurements and the origin and regulation of extracellular glutamate in rat prefrontal cortex. J Neurochem. 2010;115:1608–20. · DOI · Paper page
- Xi ZX, Baker DA, Shen H, Carson DS, Kalivas PW. Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. J Pharmacol Exp Ther. 2002;300:162–71. · DOI · Paper page
- Koike H, Chaki S. Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 2014;271:111–5. · DOI
- Joffe ME, Conn PJ. Antidepressant potential of metabotropic glutamate receptor mGlu2 and mGlu3 negative allosteric modulators. Neuropsychopharmacology. 2018;44:214–36.
- Engers JL, Rodriguez AL, Konkol LC, Morrison RD, Thompson AD, Byers FW, et al. Discovery of a selective and CNS penetrant negative allosteric modulator of metabotropic glutamate receptor subtype 3 with antidepressant and anxiolytic activity in rodents. J Med Chem. 2015;58:7485–500. · DOI
- Fukumoto K, Iijima M, Funakoshi T, Chaki S. Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine. Int J Neuropsychopharmacol. 2018;21:371–81. · DOI · Paper page
- Bjorkholm C, Marcus MM, Konradsson-Geuken A, Jardemark K, Svensson TH. The novel antipsychotic drug brexpiprazole, alone and in combination with escitalopram, facilitates prefrontal glutamatergic transmission via a dopamine D1 receptor-dependent mechanism. Eur Neuropsychopharmacol. 2017;27:411–7. · DOI
- Shinohara R, Taniguchi M, Ehrlich AT, Yokogawa K, Deguchi Y, Cherasse Y, et al. Dopamine D1 receptor subtype mediates acute stress-induced dendritic growth in excitatory neurons of the medial prefrontal cortex and contributes to suppression of stress susceptibility in mice. Mol Psychiatry. 2018;23:1717–30. · DOI
- D’Aquila PS, Collu M, Pani L, Gessa GL, Serra G. Antidepressant-like effect of selective dopamine D1 receptor agonists in the behavioural despair animal model of depression. Eur J Pharmacol. 1994;262:107–11. · DOI · Paper page
- Fukumoto K, Iijima M, Chaki S. Serotonin-1A receptor stimulation mediates effects of a metabotropic glutamate 2/3 receptor antagonist, 2S-2-amino-2-(1S,2S-2-carboxycycloprop-1-yl)-3-(xanth-9-yl)propanoic acid (LY341495), and an N-methyl-D-aspartate receptor antagonist, ketamine, in the novelty-suppressed feeding test. Psychopharmacol (Berl). 2014;231:2291–8. · DOI
- Hirota K, Okawa H, Appadu BL, Grandy DK, Devi LA, Lambert DG. Stereoselective interaction of ketamine with recombinant mu, kappa, and delta opioid receptors expressed in Chinese hamster ovary cells. Anesthesiology. 1999;90:174–82. · DOI · Paper page
- Yoon G, Petrakis IL, Krystal JH. Preliminary evidence against a role for opiate receptor signaling in the antidepressant effects of R/S-ketamine. JAMA Psychiatry. 2018;554:317–22.
- Sanacora G. Caution against over-interpreting opiate receptor stimulation as mediating antidepressant effects of ketamine. Am J Psychiatry. 2018, in press. · DOI
- Northoff G, Sibille E. Cortical GABA neurons and self-focus in depression: a model linking cellular, biochemical and neural network findings. Mol Psychiatry. 2014;19:959. · DOI
- Lin LC, Sibille E. Transcriptome changes induced by chronic psychosocial/environmental or neuroendocrine stressors reveal a selective cellular vulnerability of cortical somatostatin (SST) neurons, compared with pyramidal (PYR) neurons. Mol Psychiatry. 2015;20:285. · doi:10.1038/mp.2015.24
- Czéh B, Vardya I, Varga Z, Febbraro F, Csabai D, Martis L-S, et al. Long-term stress disrupts the structural and functional integrity of GABAergic neuronal networks in the medial prefrontal cortex of rats. Front Cell Neurosci. 2018;12:148. · DOI · Paper page
- Piantadosi SC, French BJ, Poe MM, Timic T, Markovic BD, Pabba M, et al. Sex-dependent anti-stress effect of an alpha5 subunit containing GABAA receptor positive allosteric modulator. Front Pharmacol. 2016;7:446. · DOI · Paper page
- Schiller CE, Meltzer-Brody S, Rubinow DR. The role of reproductive hormones in postpartum depression. CNS Spectr. 2015;20:48–59. · DOI · Paper page
- MacKenzie G, Maguire J. Neurosteroids and GABAergic signaling in health and disease. Biomol Concepts. 2013;4:29–42. · DOI · Paper page
- Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev. 2013;37:109–22. · DOI · Paper page
- De Simoni S, Schwarz AJ, O’Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage. 2013;64:75–90. · DOI
Cited by
Hare, B. D., & Duman, R. S. (2020) · Molecular Psychiatry · doi:10.1038/s41380-020-0685-9 · Cited by 366
Self-citationAls, T. D., Kurki, M. I., Grove, J., Voloudakis, G., Therrien, K., Tasanko, E., Nielsen, T. T., Naamanka, J., Veerapen, K., Levey, D. F., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02352-1 · Cited by 324
Pitsillou, E., Bresnehan, S. M., Kagarakis, E. A., Wijoyo, S. J., Liang, J., Hung, A., & Karagiannis, T. C. (2020) · Molecular Biology Reports · doi:10.1007/s11033-019-05129-3 · Cited by 206
Yang, C., Yang, J., Luo, A., & Hashimoto, K. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0624-1 · Cited by 190
Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine
Deyama, S., & Duman, R. S. (2020) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2019.172837 · Cited by 186
Self-citation
Metadata
- Authors
- Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B.
- Venue
- Molecular Psychiatry
- Published
- 2019-03-20
- Volume
- 24
- Issue
- 12
- Pages
- 1816-1832
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2923276583
- Cited by
- 154
- References
- 90
- FWCI
- 11.36
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH045481, MH093897)
- State of Connecticut Department of Mental Health and Addiction Services
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. https://app.cochat.ai/papers/10.1038/s41380-019-0400-x
- The paper
- Duman, R. S., Shinohara, R., Fogaça, M. V., & Hare, B. (2019). Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. Molecular Psychiatry. https://doi.org/10.1038/s41380-019-0400-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.